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Objectives. To compare the prevalence of gastrointestinal (GI) disorders in rheumatoid arthritis (RA) versus non-RA subjects and
to describe determinants of GI disorders in RA. Methods. The bowel disease questionnaire was completed by RA and non-RA
subjects. RA patients also completed the health assessment questionnaire (HAQ). Results. The study responders included 284 RA
and 233 non-RA subjects. Abdominal pain/discomfort, postprandial fullness, nausea, and stool leakage were signiﬁcantly more
commonin RA versus non-RA (odds ratios [OR] = 1.8; 1.9; 4.0;8.2, resp.). The use of laxatives,proton pump inhibitors,NSAIDs,
acetaminophen,andnarcoticswasmorecommonlyreported inRAversus non-RA(OR =2.0;1.7;3.0;2.0;1.9,resp.).Age< 60and
HAQ ≥ 1 were associated with dyspepsia, irritable bowel syndrome, gastroesophageal reﬂux disease, and GI symptom complex
overlap in RA. Conclusion. Several upper and lower GI disorders were signiﬁcantly more prevalent in RA versus non-RA subjects.
Age <60 and physical function impairment (HAQ ≥ 1) were associated with GI disorders in RA.
1.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune inﬂam-
matory disease aﬀecting ∼1% of the adult population and
associated with progressive deterioration of joint function,
increased morbidity, and mortality [1–3]. Upper gastroin-
testinal (GI)disease is recognized as oneof the major comor-
bidities in RA leading to a signiﬁcant increase in the risk of
mortality [3–8]. The evidence of increased GI risk in RA is
mostly based on the studies of organic GI disorders and GI
complications [3–5, 9–12], while functional GI symptoms
in RA are much less well characterized [6, 13]. The reasons
for the excess GI risk, particularly the risk of functional GI
disorders, are not completely understood, and the impact of
RAonincreased GI morbidity is uncertain. To study thebur-
den of GI disorders in RA patients (particularly functional
GI symptoms that may not come to medical attention), we
conducted a cross-sectional population-based survey exam-
ining the prevalence of functional GI symptoms and syn-
dromes in RA patients versus non-RA subjects. We also
aimed to deﬁne the risk factors associated with GI disorders
in RA.
2.Methods
2.1. Study Sampling and Design. Using the resources of the
Rochester Epidemiology Project [14], a population-based
medical record linkage system that allows ready access to
the complete medical records from all community medical
providers,wehavepreviouslyassembledacohortofresidents
of Olmsted County, Minnesota, aged ≥ 18 years who ﬁrst
fulﬁlled ≥4 1987American College of Rheumatology criteria
for RA [15] between 1/1/1980 and 1/1/2008. From this2 Gastroenterology Research and Practice
cohort, we identiﬁed 493 eligible RA subjects, namely those
alive and residing in Olmsted County, Minnesota as of
1/1/2008. Data were collected on rheumatoid factor (RF)
tests performed clinically for these patients.
A similar number (n = 493) of non-RA subjects selected
from the same population were matched for age, sex, and
observational period to the RA patients. Every person in the
community ≥18 years of age who was qualiﬁed during the
deﬁnedperiodregardless ofrace,ethnicity,orsocioeconomic
status was equally eligible to participate. The study protocol
was approved by Review Boards from Mayo Clinic and
Olmsted Medical Center.
We conducted a population-based cross-sectional survey
of the occurrence of GI symptoms among RA and non-RA
subjects using the bowel disease questionnaire (BDQ) [16].
RA patients also completed the health assessment question-
naire (HAQ) [17, 18]. The surveys were mailed and returned
between August 1, 2008 and December 31, 2008 in Olmsted
County, Minn, USA. Subjects who returned a completed
questionnaire were considered responders to this survey, and
those from whom we did not receive a completed question-
naire were considered nonresponders to the survey.
2.2. Bowel Disease Questionnaire. The original BDQ was
designed and validated at the Mayo Clinic as a self-report
instrument to measure GI symptoms experienced over the
prior year and to collect medical history data [16, 19]. The
BDQhasbeenshown todiscriminate functional GIdisorders
and health in the general population [16]. In the present
study, we used the shortened version of the questionnaire
with 15 questions covering a number of upper and lower GI
symptoms, including abdominal pain/discomfort, dyspha-
gia, heartburn, nausea, vomiting, early satiety, postprandial
fullness, abdominal bloating, bowel habits, and appearance
and frequency of stools. The questionnaire also included
questionsoncurrentandpastdruguse(primarily,GI-related
medications, analgetics/antipyretics, and nonsteroidal anti-
inﬂammatory drugs (NSAIDs)).
2.3. Deﬁnitions of GI Syndromes. Based on the responses to
the BDQ, the study subjects were classiﬁed as having dys-
pepsia, functional constipation, irritable bowel syndrome
(IBS), and/or gastroesophageal reﬂux disease (GERD) using
modiﬁed Rome II criteria [20]. Dyspepsia was deﬁned based
on the presence of 1 or more of the following symptoms: (a)
frequent upper abdominal pain occurring ≥1 day a week in
thepastyear;(b)earlysatiety ≥1dayaweek;(c)postprandial
fullness ≥1 day a week. We additionally analyzed thenumber
ofpatientshavingeitherdyspepsia ortreatment withproton-
pump inhibitors, H2 antagonists, or gastroprotective agents.
IBS was deﬁned as abdominal pain or discomfort ≥1d a ya
month in the past year, and given this, 2 out of the following
3 features: (a) relieved with defecation; (b) onset associated
with a change in frequency of stool; (c) onset associated
with a change in form (appearance) of stool. Functional
constipation was deﬁned when the patient had insuﬃcient
criteria forIBSbutfulﬁlled 2 ormore ofthefollowing: (a)<3
bowel movements per week; (b) strain often to have a bowel
movement; (c) stools often hard; (d) incomplete evacuation.
Inaddition,weanalyzedthenumberofpatientshavingeither
functional constipationorusing laxatives.GERDwas deﬁned
as weekly or more frequent heartburn or acid regurgitation.
If a subject met the criteria for 2 or more of the above
disorders, we deﬁned him as having “GI symptom complex
overlap.” If a subject did not meet the criteria of any of the
above disorders, we deﬁned him as having “no functional GI
disorders.”
2.4. Health Assessment Questionnaire (HAQ). HAQ is a self-
report questionnaire which is widely used for assessment
of functional disability in patients with rheumatic diseases,
particularly, in RA [17, 18]. The HAQ includes questions
regarding patient’s ability to perform activities of daily living
(summarized as HAQ disability index; scored 0–3), and
visual analog scales (0–100mm) for pain and general well-
being. As the scores increase, so do the levels of disability,
pain, and theleveloftheoverallwellness aﬀectedbyarthritis,
respectively.
2.5. Statistical Methods. Descriptive statistics were used to
summarize demographics and GI events in both cohorts, as
well as RA characteristics in the RA cohort. Comparisons
between the two cohorts were performed using Chi-square
tests and t-tests, as were comparisons between responders
and nonresponders. Logistic regression models were used
to compare the prevalence of GI symptoms and syndromes
between the RA and non-RA cohorts adjusting for age,
sex, and obesity (body mass index [BMI] ≥ 30kg/m2)w i t h
additional adjustment for the use of NSAIDs. Multivari-
able logistic regression models were performed considering
demographics (age categorized as <60 and ≥60 years; sex),
lifestyle factors(smoking, alcoholconsumption),obesity,RA
characteristics (RF positivity and HAQ score categorized as
<1a n d≥1), and NSAIDs use as potential factors associated
with GI syndromes in RA.
3.Results
3.1. Patients’ Characteristics. The study population included
284 RA and 233 non-RA subjects who responded to the
survey. This yielded a response rate of 58% and 47% in
RA and non-RA cohorts, respectively. The characteristics of
both cohorts are summarized in Table 1. The mean (SD) age
in the RA cohort was 62.4 (13.4) years (72% female) and
in the non-RA cohort was 63.6 (13.4) years (71% female).
The mean (SD) BMI estimates were similar in RA patients
and non-RA subjects: 29.0 (5.8) and 29.5 (6.8), respectively.
There were no signiﬁcant diﬀerences in alcohol and tobacco
use between RA and non-RA subjects, but RA subjects were
somewhat more likely to have a history of smoking (46%
versus 39%, P = 0.12; Table 1).
The mean (SD) RA duration was 10.3 (7.2) years, and
188 (67%) RA patients were positive for RF (Table 2). The
mean (SD) HAQ score was 0.6 (0.6). The mean (SD) patient
reported pain in the past week due to illness on the visual
analogue scale was 28.8 (24.8), and overall wellness aﬀectedGastroenterology Research and Practice 3
Table 1: Characteristics of RA and non-RA cohorts.
Variable RA
(n = 284)
Non-RA
(n = 233) P value∗
Mean age, years (SD) 62.4 (13.4) 63.6 (13.4) 0.39
Female, n (%) 204 (72) 165 (71) 0.80
Mean BMI, kg/m2 (SD) 29.0 (5.8) 29.5 (6.8) 0.69
Alcoholic drinks,
number per week 0.80
<1/week, n (%) 192 (68) 151 (65)
1–6/week, n (%) 70 (25) 62 (27)
≥7/week, n (%) 22 (8) 20 (9)
Ever Smoker,n (%) 129 (46) 92 (39) 0.12
RA: rheumatoid arthritis; SD: standard deviation; BMI: body mass index.
∗P v a l u ei n d i c a t e st h ed i ﬀerences between RA and non-RA cohorts.
by arthritis was 23.8 (23.6). Demographics and RA charac-
teristics were similar in RA patients who responded to the
survey versus nonresponders to the survey (Table 2).
3.2. GI Symptoms and Syndromes in RA versus Non-RA
Cohort. GI symptoms were found to be very common in
bothRApatientsandinnon-RAsubjects.Themostcommon
GI complaints in both RA patients and non-RA subjects
were abdominal pain/discomfort (18% and 10%, resp.) and
postprandial fullness (18% and 10%, resp.; Table 3). How-
ever, the prevalence of several GI symptoms was higher in
RA patients than in non-RA subjects, even after adjustment
for age, sex, and obesity (BMI ≥ 30kg/m2). In particular,
RA patients were more likely than non-RA subjects to
experience abdominal pain/discomfort (odds ratio [OR] 1.8,
95% conﬁdence interval [CI] 1.1, 3.1), postprandial fullness
(OR1.9,95% CI 1.1,3.3),nausea (OR4.0, 95%CI 1.1,14.2),
and stool leakage (OR 8.2, 95% CI 1.03, 66). The likelihood
of dyspepsia in RA versus non-RA subjects approached
statistical signiﬁcance (OR 1.6, 95% CI 0.9, 2.8; P = 0.10).
No signiﬁcant diﬀerences were found between RA and non-
RA subjects for GI syndromes, including functional con-
stipation, IBS, and GERD. The likelihood of having GI
symptom complexoverlap,aswell asthelikelihoodofhaving
no functional GI disorders, was similar in the RA and non-
RA cohorts. The odds ratios for these associations changed
only minimally after the additional adjustment for NSAIDs
(data not shown).
3.3. Medication Usage in RA versus Non-RA Cohort. RA pa-
tients were more likely than non-RA subjects to take med-
ications for their GI disorders (Table 3). These included
laxatives (OR 2.0, 95% CI 1.1, 3.5) and proton pump
inhibitors (OR 1.7, 95% CI 1.1, 2.5). The likelihood of using
H2 antagonists in RA versus non-RA subjects approached
statistical signiﬁcance (OR 1.6, 95% CI 0.95, 2.7; P = 0.08).
The proportion of those having dyspepsia or using medi-
cations for dyspepsia (namely, proton-pump inhibitors, H2
antagonists, or gastroprotective agents) was 1.9-fold higher
in RA versus non-RA cohort (Table 3). Not surprisingly,
RA patients took more NSAIDs (OR 3.0, 95% CI 1.8, 5.0),
acetaminophen (OR 2.0, 95% CI 1.2, 3.4), and narcotic
medications (OR 1.9, 95% CI 1.2, 3.0) as compared to non-
RA subjects. The intake of other medications (i.e., antispas-
modics,antacids, gastroprotectiveagents,antidiarrheal med-
ications, antidepressants, and calcium channel blockers) was
similar in both the RA and non-RA cohorts. After adjusting
for age, sex, and obesity, further adjusting for NSAIDs did
not substantially change the results (data not shown).
3.4. Factors Associated with GI Syndromes in RA. For RA
patients, we further examined the associations of demo-
graphics(age categorized as <60and ≥60 years; sex), lifestyle
factors (smoking, alcohol consumption),obesity, RAcharac-
teristics (RF positivity and HAQ score categorized as <1a n d
≥1), and NSAIDs with each of the GI syndromes (dyspepsia,
functional constipation, IBS, GERD, and GI symptom com-
plex overlap) using multivariable models assessing all factors
of interest simultaneously. The results of these analyses
are summarized in Table 4. Dyspepsia, IBS, GERD, and GI
symptom complex overlap were more likely to occur in RA
patients aged <60 years, than in those who were ≥60 years
as well as among the patients with HAQ score ≥1c o m p a r e d
to those with HAQ score <1. RA patients <60 years were
less likely to be free of GI disorders than those aged ≥
60 years. The association of other potential GI risk factors
(including gender, obesity, smoking, alcohol consumption,
and RF positivity) and NSAIDs use with GI syndromes did
not reach statistical signiﬁcance (P>0.25 for all).
4.Discussion
We report the results of a population-based survey of GI
symptoms and syndromes in RA patients compared to
matched non-RA subjects from the same population. This
studydemonstratedtheincreasedprevalenceofseveralupper
and lower GI symptoms such as abdominal pain/discomfort,
postprandial fullness, nausea, and stool leakage in RA
patients as compared to the non-RA subjects. Further, we
observed a higher prevalence of GI symptoms occurring at
least once a week (i.e., very often) in RA patients compared
to non-RA subjects. We have also found the more frequent
use of some GI-related medications, particularly laxatives
and proton pump inhibitors in RA compared to the non-
RA subjects. Our results are concordant with previous
observations showing higher prevalence of the dysmotility-
like symptoms in some rheumatological disorders including
RA [6, 13] .T h en a t u r eo ft h e s ef u n c t i o n a lG Id i s o r d e r s
remains uncertain.
One potential reason for this increased burden of func-
t i o n a lG Id i s o r d e r si nR Ai st h ee ﬀect of antirheumatic med-
ications [9–11, 21–30]. In fact, GI disease in RA has been
extensively studied in the context of drug-related upper GI
complications,and theadverse eﬀectsofantirheumatic med-
ications (particularly, NSAIDs) have been clearly demon-
strated [21–30]. However, recent evidence suggests that
the implementation of the guidelines for prevention of
NSAID-gastropathy may lead to the decrease in NSAID-
associated GI events [12, 31, 32]. Concordantly, we did not4 Gastroenterology Research and Practice
Table 2: Demographics and RA characteristics in survey responders and nonresponders to the survey among patients with rheumatoid
arthritis.
Variable Responders to the survey
(N = 284)
Nonresponders to the survey
(N = 209) P value∗
Mean age on the date of response, years (SD) 62.4 (13.4) 61.0 (15.4) 0.16
Female, n (%) 204 (72) 155 (74) 0.57
Mean duration of RA, years (SD) 10.3 (7.2) 9.8 (6.9) 0.55
RF positive, n (%) 188 (67) 141 (68) 0.79
∗P v a l u ei n d i c a t e st h ed i ﬀerences between survey responders and nonresponders to the survey.
Abbreviations: RA: rheumatoid arthritis; SD: standard deviation; RF: rheumatoid factor.
Table 3: Gastrointestinal complaints and medications in RA and non-RA cohortsa.
Variable RA
(n = 284)
Non-RA
(n = 233)
Odds ratiob (95% CI) adjusting for age,
sex, and obesity (BMI ≥ 30kg/m2)
GI symptoms (≥1 day per week)
Abdominal pain/discomfort 52 (18) 24 (10) 1.8 (1.1,3.1)
Early satietyc 30 (12) 19 (9) 1.3 (0.7, 2.3)
Postprandial fullnessd 47 (18) 22 (10) 1.9 (1.1,3.3)
Nausea 15 (6) 3 (1) 4.0(1.1,14.2)
Stool leakage 10 (4) 1 (0.4) 8.2(1.03,66)
GI syndromes
Dyspepsia 43 (16) 22 (10) 1.6 (0.9, 2.8)
- Dyspepsia or treatment with proton-pump
inhibitors, H2 antagonists,or gastroprotective
agents
132(46) 72 (31) 1.9 (1.3,2.7)
Functional constipation 82 (29) 67 (29) 1.1 (0.7, 1.6)
- Functional constipation or laxative use 116 (41) 84 (36) 1.3 (0.9, 1.9)
Irritable bowel syndrome 82 (29) 59 (26) 1.1 (0.7, 1.6)
Gastroesophageal reﬂux disease 41 (14) 26 (11) 1.4 (0.8, 2.3)
GI symptom complex overlap 50 (18) 28 (12) 1.4 (0.8, 2.4)
No functional GI disorders 103 (36) 94 (40) 0.9 (0.6, 1.2)
Medications
Laxatives 43 (16) 20 (9) 2.0 (1.1,3.5)
Proton-pump inhibitors 89 (32) 48 (21) 1.7 (1.1,2.5)
Gastroprotective agents (sucralfate, misoprostol) 9 (3.2) 2 (0.9) 3.7 (0.8, 17.6)
H2 antagonists 46 (16) 25 (11) 1.6 (0.95, 2.7)
NSAIDs, ≥7tab./cap per week 73 (26) 26 (11) 3.0 (1.8,5.0)
Acetaminophen, ≥7tab. per week 58 (21) 26 (11) 2.0 (1.2,3.4)
Narcotic pain medications 68 (24) 34 (15) 1.9 (1.2,3.0)
Iron supplements 49 (18) 27 (12) 1.6 (0.9, 2.6)
aAll data are shown as n (%).
bOdds ratio compares RA to non-RA; signiﬁcant (P<0.05) odds ratios are shown in bold.
cDeﬁned as inabilityto ﬁnish a regular-sized meal.
dDeﬁned as feeling too full after a regular-sized meal.
Abbreviations: GI: gastrointestinal; RA: rheumatoid arthritis; NSAIDs: nonsteroid anti-inﬂammatory drugs.
ﬁnd theassociation ofNSAIDsuse with GIsyndromes in our
study.
Alternatively, GI disorders may be a part of the clinical
spectrum of RA disease [5, 33]. In this study, we observed an
association of physical function impairment (i.e., higher
HAQscore)withanumberofGIsyndromes. Whiledisability
itself can cause diﬃculties with usual activities in RA pa-
tients, this association raises the possibility that active sys-
temic inﬂammation may play a role in the development of
GI disorders. Others have observed that RF seropositive RA
patients are more likely to develop GI bleeding compared to
RF seronegative patients [11]. Although our study did notGastroenterology Research and Practice 5
Table 4: Multivariable models of variables# associated with GI syndromes in RA patients.
Variables Dyspepsia Functional
constipation IBS GERD GI symptom
complex overlap
No functional GI
disorders
Age < 60yrs 2.5 (1.2,5.4) 0.6 (0.4, 1.1) 1.9 (1.1,3.4) 2.8 (1.3,6.0) 2.2(1.1,4.4) 0.5 (0.3,0.9)
Female sex 2.3 (0.8, 6.6) 0.6 (0.3, 1.1) 1.4 (0.7, 2.8) 0.6 (0.3,1.4) 1.4 (0.6, 3.3) 1.3 (0.7, 2.4)
HAQ ≥1 2.4 (1.1,5.1) 0.6 (0.3, 1.1) 2.4 (1.3,4.5) 3.2 (1.5,7.1) 3.1(1.5,6.3) 0.7 (0.4, 1.3)
RF positivity 1.0 (0.4, 2.1) 1.0 (0.6, 1.9) 1.2 (0.7, 2.2) 1.2 (0.5, 2.6) 1.0 (0.5, 2.1) 0.8 (0.5, 1.3)
Obesity (BMI ≥ 30kg/m2) 1.1 (0.5, 2.4) 1.0 (0.6, 1.9) 0.9 (0.5, 1.6) 0.9 (0.4, 1.9) 0.9 (0.4, 1.8) 1.1 (0.6, 1.8)
NSAIDs use 1.4 (0.7, 3.2) 0.8 (0.4, 1.5) 1.5 (0.8, 2.8) 0.8 (0.4, 1.9) 1.2 (0.6, 2.5) 0.9 (0.5, 1.7)
Smoking 1.3 (0.6, 2.8) 1.1 (0.6, 2.0) 1.0 (0.6, 1.8) 0.5 (0.2, 1.1) 0.8 (0.4, 1.6) 1.0 (0.6, 1.7)
Alcohol use 2.0 (0.6, 6.8) 1.0 (0.4, 2.6) 0.4 (0.1, 1.5) 1.3 (0.3, 5.0) 1.6 (0.5, 5.2) 1.7 (0.7, 4.3)
#Signiﬁcant (P<0.05) odds ratios are shown in bold.
A b b r e v i a t i o n s :G I :g a s t r o i n t e s t i n a l ;R A :r h e u m a t o i da r t h r i t i s ;I B S :i r r i t a b l eb o w e ls y n d r o m e ;G E R D :g a s t r o e s o p h a g e a lr e ﬂ u xd i s e a s e ;H A Q :h e a l t h assessment
questionnaire; RF: rheumatoid factor; BMI: body mass index; NSAIDs: nonsteroidal anti-inﬂammatory drugs.
demonstrate a signiﬁcant association between RF positivity
and GI syndromes, this may be due to the lack of power and
requires further elucidation.
Our observation of higher likelihood of GI syndromes in
RApatientsaged<60y ea r sth a ni nth os e≥60years indirectly
corroborates with the previous ﬁndings on the lower fre-
quency of GI symptoms in older ages in general population
and may be linked to changes in visceral sensitivity with
aging [34, 35]. The alternative explanation could be a possi-
bility of confounding by indication when patients ≥60 years
at risk for GI complications receive more gastroprotective
treatment, thus leading to the lower frequency of GI disor-
ders. Consistent with previous studies of the general popu-
lation [36, 37], smoking and alcohol consumption were not
signiﬁcantly associated with GI disorders.
The results of this study should be interpreted in the
context of several limitations. First, despite the large num-
ber of subjects in both the RA and non-RA cohorts,
statistical power is limited for some comparisons due
to the infrequency of some GI events. Thus, we may not have
been able to demonstrate statistical signiﬁcance for some
important clinical diﬀerences. Secondly, due to the cross-
sectional design, we captured only prevalent GI symptoms.
Thus, some GI symptoms with short duration could have
been missed. However, considering that GI disorders are
predominantly chronic conditions and that subjects were
asked to report GI symptoms during the past year, we believe
that the cross-sectional design was appropriate and provided
reliable information on GI symptoms in our study. Third,
the results of the study are based on patient self-report,
w h i c hi ss u b j e c tt or e c a l lb i a s .H o w e v e r ,t h i sb i a si sl i k e l yt o
be nondiﬀerential as the limitation applied equally to both
the RA and non-RA cohorts. Further, the use of a standard-
ized validated questionnaire which previously demonstrated
adequate performance in the general population is likely to
minimize this weakness. Fourth, there is a possibility of
nonresponse bias, but no signiﬁcant diﬀerences in the char-
acteristics of survey respondents versus nonrespondents to
the survey were found. Fifth, during this survey, we did not
collect information on serious GI complications (including
GI ulcer, GI bleed, GI perforation, and bowel obstruction),
antirheumatic medications (including biologics), antiosteo-
porotic medications, and comorbidities for each patient.
However,fromourotherstudiesofthiscohort,we knowthat
only a small percentage (roughly 16%) have used biologics,
so it is unlikely that the use of biologics has a signiﬁcant
impact on our results. Epidemiology and impact of serious
GI events in RA is subject of our ongoing study. Lastly, the
population of Olmsted County, Minnesota is predominantly
Caucasian suggesting that the results of the study may not be
generalizabletomore ethnicallydiversepopulations.Notable
strengths of the study include a population-based study
design with a comparison cohort of non-RA subjects from
thesamepopulationandtheuseofavalidatedquestionnaire.
In conclusion, several upper and lower GI disorders are
signiﬁcantly more prevalent in RA patients compared to the
general population. RA patients are more likely to take anal-
gesic medications, laxatives, and proton-pump inhibitors
than non-RA subjects. Younger age (<60 years) and physical
function impairment (HAQ score ≥1) are associated with
some GI syndromes in RA. This raises the possibility that
the impact of RA on GI disease is more widespread than
previously believed. Together these ﬁndings suggest that
there is need for the increased awareness ofthe GI symptoms
inRA.Moreresearch isneededto furtherexamine the nature
of GI disorders in RA.
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